China's Feihe Exports Science, Not Just Formula, to Win Southeast Asia

SINGAPORE – March 31, 2026 – In an auditorium at the National University of Singapore (NUS), a collection of the world's most distinguished neuroscientists recently convened to explore the frontiers of brain development. Meanwhile, a few hours away by plane, a mother in a Mindanao Island shopping mall carefully selected a can of infant formula, a choice representing a new chapter in a rapidly evolving global market.

These two scenes, though geographically and contextually distinct, are threads in the same intricate story: the strategic expansion of Feihe, China's largest infant formula producer, into Southeast Asia. The company is not merely shipping products across borders; it is pioneering a new model of globalization for Chinese brands, one where scientific leadership and research ecosystems are exported alongside consumer goods.

This month's "Bridging Minds—2026 Advances in Neurodevelopment and Mental Health" summit, held at NUS and co-organized by Feihe with prestigious partners like Harvard Medical School and Boston Children's Hospital, serves as the cornerstone of this ambitious strategy. It signals a departure from the traditional multinational playbook of developing products in the West and marketing them to the rest. Instead, Feihe is embedding itself within the global scientific community to define the very standards of the products it sells.

A New Blueprint for 'Going Global'

The old model of corporate expansion is being turned on its head. For decades, multinational corporations established R&D hubs in Europe or North America, perfecting products before exporting them to emerging markets. Feihe is charting a different course. By funding foundational research at world-class institutions, fostering scientific dialogue in a regional hub like Singapore, and translating those findings directly into products for local consumers, the company is creating a closed-loop system of innovation and commercialization.

"We are evolving from learners in global research to active participants—and even definers," stated Feihe Chairman Leng Youbin during the summit. His words echo a broader trend among China's leading companies. From electric vehicle maker BYD outselling competitors in Singapore to lifestyle brand POP MART launching flagship stores, Chinese brands are increasingly exporting not just goods, but also technology, standards, and scientific influence.

The "Bridging Minds" summit exemplifies this shift. Bringing together top academics from institutions like Yale, Tsinghua, and Fudan, the event positioned Feihe not as a mere sponsor, but as an active contributor to the scientific discourse on neuroscience and life cycle nutrition. Hosting the event in Singapore was a deliberate choice. The city-state is not only a financial powerhouse but also a critical hub for life sciences research in Asia, making it an ideal "bridgehead" for any company serious about deepening its presence in the region.

This approach suggests that for Feihe, Southeast Asia is more than a new sales territory; it is an integral part of its global research and development ecosystem. The strategy aims to build credibility from the laboratory up, creating a foundation of scientific validation that resonates with increasingly discerning consumers.

The Battle for Southeast Asia's Shelves

While Feihe's academic pursuits build its brand, its commercial success will be determined on the competitive shelves of Southeast Asian retailers. The region's infant formula market is a formidable battleground, projected to see significant growth driven by rising incomes, urbanization, and a growing number of working mothers. In Indonesia alone, the infant nutrition market is estimated at $9.33 billion in 2025 and is expected to grow at a CAGR of 9.2% through 2030. The Philippines market is also expanding steadily, with parents prioritizing trusted brands and safe, high-quality ingredients.

Feihe entered this dynamic landscape in 2025, starting with the Philippines. Its flagship product, AceKid Activegro, was designed to stand out. The company is leveraging its signature "One-Step Fresh Milk Processing" method, which uses fresh milk from its integrated supply chain within two hours of milking, a process designed to preserve natural active nutrients. This "Fresh and Active Nutrition" standard, honed in China's highly demanding market where Feihe has been the top seller for seven consecutive years, is now its key differentiator abroad.

Crucially, AceKid Activegro is formulated without added sucrose or maltodextrin—ingredients that health experts link to increased risks of tooth decay and metabolic issues in children. This formulation directly addresses the growing demand from health-conscious parents for cleaner, more natural products. The strategy appears to be working. Since its launch, AceKid Activegro has secured placement in nearly 500 stores, covering an estimated 80% of the Philippines' high-end retail network. The company reported staggering growth in the first quarter of 2026, with revenue climbing 275% year-on-year.

Building on this momentum, Feihe recently achieved a major regulatory victory: AceKid Activegro was approved for sale in Indonesia, becoming the first Chinese infant formula brand authorized in the country. Navigating Indonesia's stringent National Agency of Drug and Food Control (BPOM) regulations is a significant hurdle that demonstrates the company's commitment to meeting high international standards, positioning it to challenge established Western incumbents like Nestlé and Danone.

Beyond the Bottle: A Lifecycle Nutrition Vision

Feihe's ambitions extend far beyond infant nutrition. The company is strategically repositioning itself as a comprehensive milk protein nutrition expert, aiming to apply its exacting standards to products for all life stages. This long-term vision is powered by a formidable global R&D network, with over 40 collaborations spanning seven countries, and a focus on building a technological moat through in-house production.

The company now produces 11 core ingredients internally, including lactoferrin, an immune-active protein often called "liquid gold" and a key component in premium formulas. This vertical integration gives Feihe unparalleled control over its supply chain and ingredient quality, a significant competitive advantage in a market where safety and traceability are paramount.

This expertise is being channeled into a new generation of products. By leveraging its breakthroughs in milk protein processing, Feihe is extending its "infant-grade standards" to items like Supernova Cheese for children and small-molecule milk protein powders designed for middle-aged and elderly consumers. This diversification strategy taps into the growing global demand for high-quality protein and specialized nutrition across different demographics.

As Feihe launches innovative products based on emerging science like the gut-brain axis, it brings more than just a new choice to Southeast Asian families. It brings a new competitive paradigm, one where a company born in the world's largest consumer market is now leveraging its scale and R&D prowess to help shape the future of the global nutrition industry.